Feb 10 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS CONSIDERS ADDING LUNG SCARRING AS AN ADDITIONAL ENDPOINT FOR ITS PHASE 2B/3 COVID-19 STUDY PROTOCOL
Feb 10 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS CONSIDERS ADDING LUNG SCARRING AS AN ADDITIONAL ENDPOINT FOR ITS PHASE 2B/3 COVID-19 STUDY PROTOCOL